2026-04-17T05:48:09Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1649432025-12-05T16:26:32Zcom_2072_1057col_2072_478917col_2072_478921

00925njm 22002777a 4500 dc Iglesias, Pablo author Ribero, Simone author Barreiro Capurro, Alicia author Podlipnik, Sebastian author Carrera Álvarez, Cristina author Malvehy, J. (Josep) author Puig i Sardà, Susana author 2020-06-09T11:38:34Z 2020-06-09T11:38:34Z 2019-02-01 2020-06-09T11:38:34Z Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is the first oncolytic virus approved for use in therapy for metastatic melanoma. T-VEC provides a treatment option for patients with limited metastatic disease. T-VEC is a genetically modified, live, attenuated herpes simplex virus type 1 designed to replicate in tumour cells and promote an enhanced anti-tumour response (1) T-VEC is administered by injection into cutaneous, subcutaneous or nodal lesions, which are visible and/or palpable and/ or visualized by ultrasonography (2). Other local management options have been used to control metastatic disease in stage IIIB, but almost all have shown only a local effect and rapid disease relapse (3, 4). With T-VEC, responses occurred in injected and uninjected lesions, including a greater than 50% decrease in size in 15% of uninjected visceral lesions. The appearance of vitiligo has been described as an adverse event after administration of immune checkpoint inhibitors (5, 6). It has been reported as a marker of activity of the drug and long-term results, inducing clinicians to use it as a predictor of drug response (7). A T-VEC phase II study has reported 85% adverse events, all of which were grade 1 or 2. The appearance of vitiligo has been described in 3 patients out of 50 (8), although no details regarding duration and appearance have been reported. Càncer de pell Vitiligen Melanoma Skin cancer Vitiligo Melanoma Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response